Fulltext

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial

Kamm, Christian ; El-Koussy, Marwan ; Humpert, Sebastian ; Findling, Oliver ; von Bredow, Ferdinand ; Burren, Yuliya ; Schwegler, Guido ; Schött, Dagmar ; Donati, Filippo ; Müller, Martin ; Goebels, Norbert ; Müller, Felix ; Slotboom, Johannes ; Tettenborn, Barbara ; Kappos, Ludwig ; Naegelin, Yvonne ; Mattle, Heinrich

In: Journal of Neurology, 2012, vol. 259, no. 11, p. 2401-2413

Ajouter à la liste personnelle
    Titre
    • Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
    Auteur
    • Kamm, Christian. University Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
    • El-Koussy, Marwan. Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
    • Humpert, Sebastian. University Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
    • Findling, Oliver. University Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
    • von Bredow, Ferdinand. Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
    • Burren, Yuliya. Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
    • Schwegler, Guido. Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland
    • Schött, Dagmar. Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
    • Donati, Filippo. Department of Neurology, Spitalzentrum Biel, Biel, Switzerland
    • Müller, Martin. Department of Neurology, Cantonal Hospital Lucerne, Lucerne, Switzerland
    • Goebels, Norbert. Department of Neurology, University Hospital Zurich, Zurich, Switzerland
    • Müller, Felix. Department of Neurology, Cantonal Hospital Thurgau, Muensterlingen, Switzerland
    • Slotboom, Johannes. Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
    • Tettenborn, Barbara. Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
    • Kappos, Ludwig. Department of Neurology, University Hospital, University of Basel, Basel, Switzerland
    • Naegelin, Yvonne. Department of Neurology, University Hospital, University of Basel, Basel, Switzerland
    • Mattle, Heinrich. University Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:322138
    Summary
    Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. The present study evaluated the effect of atorvastatin added to interferon beta-1b in multiple sclerosis (MS) in a multicenter, randomized, parallel-group, rater-blinded study performed in eight Swiss hospitals. Seventy-seven patients with relapsing-remitting MS started interferon beta-1b every other day. After 3months, they were randomized 1:1 to receive atorvastatin 40mg/day or not in addition to interferon beta-1b until month 15. The primary endpoint was the proportion of patients with new lesions on T2-weighted images at month 15 compared to baseline at month three. At study end, the proportion of patients with new lesions on T2-weighted images was equal in both groups (odds ratio 1.14; 95% CI 0.36-3.56; p=0.81). All predefined secondary endpoints including number of new lesions and total lesion volume on T2-weighted images, total number of new Gd-enhancing lesions on T1-weighted images, total brain volume, volume of grey matter, volume of white matter, EDSS, MSFC, relapse rate, time to first relapse, number of relapse-free patients and neutralizing antibodies did not show any significant differences (all p values >0.1). Transient elevations of liver enzymes were more frequent with atorvastatin (p=0.02). In conclusion, atorvastatin 40mg/day in addition to interferon beta-1b did not have a beneficial effect on relapsing-remitting MS compared to interferon beta-1b monotherapy over a 12-month period